Department of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
Exp Hematol Oncol. 2012 Apr 26;1(1):11. doi: 10.1186/2162-3619-1-11.
To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma.
Randomized phase II and III trials on CIK cell-based therapy were identified by electronic searches using a combination of "hepatocellular carcinoma" and "cytokine-induced killer cells".
The analysis showed significant survival benefit (one-year survival, p < 0.001; two-year survival, p < 0.001; median overall survival, p < 0.001) in favor of CIK-based therapy. Comparison of CIK group versus non-CIK group resulted in a significantly prolonged progression-free survival (PFS) (p < 0.01). A favored disease control rate (DCR) and overall response rate (ORR) were also observed in patients receiving CIK cell therapy (p < 0.01). Meanwhile, patients in the CIK group showed better quality of life (QoL), diminished HBV-DNA content and AFP level (p < 0.01). Comparing T-lymphocyte subsets in peripheral blood, the analysis showed the ratio of CD3+, CD4+, CD4+CD8+ and CD3+CD4+ T cells significantly increased in the CIK group, compared with the non-CIK group (p < 0.01).
CIK cell therapy demonstrated a significant superiority in prolonging the median overall survival, PFS, DCR, ORR and QoL of HCC patients. These results support further larger scale randomized controlled trials for HCC patients with or without the combination of other therapeutic methods.
评估细胞因子诱导的杀伤（CIK）细胞疗法治疗肝细胞癌的疗效。
通过电子检索，使用“肝细胞癌”和“细胞因子诱导的杀伤细胞”的组合，确定了基于 CIK 细胞的治疗的随机 II 期和 III 期试验。
分析显示，CIK 基疗法具有显著的生存获益（一年生存率，p<0.001；两年生存率，p<0.001；中位总生存期，p<0.001）。CIK 组与非 CIK 组相比，无进展生存期（PFS）明显延长（p<0.01）。接受 CIK 细胞治疗的患者也观察到疾病控制率（DCR）和总缓解率（ORR）较高（p<0.01）。同时，CIK 组患者的生活质量（QoL）较好，HBV-DNA 含量和 AFP 水平降低（p<0.01）。比较外周血 T 淋巴细胞亚群，分析显示 CIK 组 CD3+、CD4+、CD4+CD8+和 CD3+CD4+T 细胞比例明显高于非 CIK 组（p<0.01）。
CIK 细胞疗法在延长 HCC 患者的中位总生存期、PFS、DCR、ORR 和 QoL 方面具有显著优势。这些结果支持进一步进行更大规模的随机对照试验，以评估 CIK 细胞疗法治疗 HCC 患者的疗效，无论是否联合其他治疗方法。
